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===================

The Gram-negative, facultative anaerobic and motile bacillus *Serratia marcescens* is an opportunistic human pathogen and a member of the *Enterobacteriaceae* ([@B1], [@B2]). It is ubiquitous in nature and has been recognized since the 1950s as an etiological agent of nosocomial infections ([@B3]), including bacteremia, pneumonia, meningitis, myocarditis, endocarditis, respiratory tract infections, urinary tract infections, and wound infections ([@B4][@B5][@B6]). Moreover, *S. marcescens* can pose a serious obstacle to antimicrobial treatment of infections due to its intrinsic and acquired resistance to a wide range of antimicrobials ([@B7], [@B8]).

*S. marcescens* strain AH0650_Sm1 was isolated from the sputum of a pneumonia patient at the Alfred Hospital Intensive Care Unit in Melbourne, Australia, on 20 March 2014. Antimicrobial susceptibility tests via the Vitek 2 system (bioMérieux, France) showed that AH0650_Sm1 was resistant to ampicillin (MIC 16), amoxicillin-clavulanic acid (MIC ≥32), ticarcillin-clavulanic acid (MIC ≤8), piperacillin-tazobactam (MIC ≤4), tobramycin (MIC 4), nitrofurantoin (MIC 256), and cefazolin (MIC ≥64); intermediately resistant to cefoxitin (MIC 16); and susceptible to amikacin (MIC ≤2), ceftriaxone (MIC ≤1), ceftazidime (MIC ≤1), cefepime (MIC ≤1), meropenem (MIC ≤0.25), gentamicin (MIC ≤1), ciprofloxacin (MIC ≤0.25), norfloxacin (MIC ≤0.5), trimethoprim (MIC ≤0.5), and trimethoprim-sulfamethoxazole (MIC ≤20). The unit of all MICs is µg/ml.

Whole-genomic DNA was extracted using phenol-chloroform and the Phase Lock Gel protocol (5PRIME), with some minor adaptations, and a barcoded library was prepared using the Nextera XT kit (Illumina, USA). Paired-end sequencing was performed at the Australian Genome Research Facility with the Illumina HiSeq 2500 system, generating 1,858,192 read pairs (2 × 125 bp) yielding 90× coverage. Reads were filtered for an average Phred quality ≥30 and assembled *de novo* using SPAdes version 3.5.0 ([@B9]) with *k*-mer lengths of 21, 33, 55, 77, and 99. SSPACE version 3.0 ([@B10]) was used for scaffolding, and GapFiller version 1.10 ([@B11]) was used for filling gaps. Contigs were further extended and reordered using AlignGraph version 27062014 ([@B12]) and ABACAS version 1.3.1 ([@B13]), respectively, with reference to the finished chromosome sequence of *S. marcescens* Db11 (RefSeq accession no. NZ_HG326223). Contigs shorter than 200 bp were removed. The final assembly was annotated using Prokka version 1.11 ([@B14]). Antimicrobial resistance genes and plasmid replicons were screened using SRST2 ([@B15]) with databases from ARG-ANNOT ([@B16]) and PlasmidFinder ([@B17]). PHAST ([@B18]) was used for identifying prophage regions. These genomic features were further investigated using nucleotide and protein BLAST.

This draft genome contains 5,201,657 bp assembled into 20 contigs with an *N*~50~ of 946 kbp. The genomic annotation includes 4,734 protein coding sequences, 88 tRNA genes, 22 rRNA genes, and one tmRNA gene. Genes related to antimicrobial resistance were identified, including variants of *tet*(41) and *tetR*(41) ([@B8]), an *aac(6′)-Ic* ([@B19]) variant, *ampC*, *ampR*, and those encoding a metallo-beta-lactamase and several multidrug efflux pumps. A putative novel prophage (31.8 kbp) was identified, which shared 75% identity with *Salmonella* phage FSL SP-004 (RefSeq GenBank accession no. NC_021774) along 60% of its length. No plasmid replicon was detected.
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This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number [LFJS00000000](LFJS00000000). The version described in this paper is the first version, LFJS00000000.1.
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